All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Advanced Obesity Drug 9604
For educational and research purposes only. Not medical advice.
AOD-9604 is a GH fragment that targets fat metabolism without growth-promoting effects. Clinical evidence is limited; Phase II obesity trials showed modest results. TGA-approved in Australia as a topical for osteoarthritis.
Best Time
Morning, fasted
Method
subcutaneous
Frequency
Daily
Half-life
~1 hour
Cycle Length
12 weeks
Storage
Refrigerate at 2-8°C.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Journal of pharmaceutical and biomedical analysis 101 :66-83 · 2014-12-01
Journal of separation science 39 (2) :333-41 · 2016-01-01
Current opinion in investigational drugs (London, England : 2000) 7 (4) :312-8 · 2006-04-01
Expert review of proteomics 11 (6) :663-73 · 2014-12-01
Sports medicine (Auckland, N.Z.) · 2026-04-12
Mechanism of Action
Modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis and inhibits lipogenesis without the growth-promoting or diabetogenic effects of full HGH.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.